Atherosclerosis predisposes patients to cardiovascular diseases, such as myocardial infarction and stroke. Instigation of vascular injury is triggered by retention of lipids and inflammatory cells in the vascular endothelium. Whereas these vascular lesions develop in young adults and are mostly considered harmless, over time persistent inflammatory and remodeling processes will ultimately damage the arterial wall and cause a thrombotic event due to exposure of tissue factors into the lumen. Evidence from human tissues and preclinical animal models has clearly established the role of cathepsin cysteine proteases in the development and progression of vascular lesions. Hence, understanding the function of cathepsins in atherosclerosis is important for developing novel therapeutic strategies and advanced point of care diagnostics. In this review we will describe the roles of cysteine cathepsins in different cellular process that become dysfunctional in atherosclerosis, such as lipid metabolism, inflammation and apoptosis, and how they contribute to arterial remodeling and atherogenesis. Finally, we will explore new horizons in protease molecular imaging, which may potentially become a surrogate marker to identify future cardiovascular events.
Introduction
The global burden of atherosclerosis remains challenging in the face of a high prevalence of obesity and its related metabolic disorders such as hyperlipidemia, diabetes mellitus and hypertension. Atherosclerosis is a chronic inflammatory disease and the most frequent cause of ischemic heart disease, stroke and premature death [1] . This slow and progressive disease involves mostly the aorta and coronary and carotid arteries, favoring the curvatures and branching points where blood flow is mostly turbulent [2] . Early atherosclerotic lesions develop as fatty streaks with deposition of lipid-engorged macrophages (also known as foam cells) under the arterial wall. Over time, these fatty streaks enlarge and form the lipid core of the atheroma, which is composed of foam cells, macrophages, T-cells, a large fibrous cap of smooth muscle cells (SMCs) and extracellular matrix (ECM) [3] . Whereas most of these vascular lesions remain harmless and show no clinical symptoms, some of them may ultimately progress into advanced lesions. These lesions are characterized by a large necrotic core of apoptotic cells, cholesterol crystals (CCs), components of the innate and adaptive immune systems and tissue remodeling proteases that collectively lessen the stability of plaques and render them prone to rupture [4] . Consequently, this stimulates a molecular cascade of platelet aggregation, thrombosis and vascular occlusion, which suddenly strikes as myocardial infarction or stroke [5] .
Studies of culprit lesions causing myocardial infarction underscore the role of proteases in the pathogenesis of cardiovascular diseases, as they are frequently characterized by a thin fibrous cap and high activity of matrix degrading proteases such as the matrix metalloproteinases and cysteine cathepsins (hereafter referred as cathepsins) [6] . This suggests that protease activity has a large impact on vascular pathology, and hence understanding the molecular mechanisms driven by protease function will provide new avenues for potential intervention points.
Cysteine cathepsin protease superfamily: structure, function and regulation
Given that proteolytic activity has a substantial impact on the transition from a stable to pathological atherosclerotic lesion, it is widely appreciated that cathepsins are pivotal in this process [7] . They belong to a broad family of the papain-like proteases, and the human genome encodes 11 proteins, namely cathepsins B, C, F, H, K, L, O, S, V/L2, W and X/Z. Most cathepsins are endopeptidases (cathepsins F, K, L, S, V), cathepsins B and H also exhibit exopeptidase activity, while cathepsins C and X/Z are strict exopeptidases [8, 9] .
Crystallographic structure and pairwise sequence alignment have revealed a highly conserved protein fold for most cathepsins, with two major domains referred to as left (L) and right (R) (Fig. 1 ) that contribute the catalytic dyad cysteine (Cys) and histidine (His) [10, 11] . These structural domains form the active site cleft with His emerging from the R domain and reactive Cys from the L domain, which drives a nucleophilic attack by an activated thiol towards the substrate's amide carbon [12] . Cathepsins are widely expressed in a variety of cells and tissues with the exception of cathepsins S and W, which are predominantly expressed in components of the immune system ( [13, 14] and see http://www.proteinatlas.org/). This broad expression pattern in conjunction with their breadth of substrates and redundancy, as discovered by proteomics studies [15, 16] and analysis of substrate libraries [17] , has led to the conception that cathepsins are physiologically involved in protein turnover and degradation. However, nowadays this view is refuted by evidence that cathepsins drive specific cellular functions such as cell cycle progression [18] or apoptosis [19] and that mice lacking the constitutively expressed cathepsin L display marked phenotypes in different tissues such as hair loss [20] or cardiomyopathy [21] .
Cathepsin expression is regulated by the transcription factors SP1, ETS1 and the lysosomal biogenesis regulator, transcription factor EB (TFEB) [22] . Since proteolysis is a rapid and irreversible process, members of the C1 papain family including cathepsins are generated as inactive zymogens and post-translationally modified by mannose 6-phosphate in the ER and Golgi to facilitate their delivery and isolation in the lysosomes [23, 24] . Lysosomal cathepsin activity is further regulated by their prodomain region, which folds on the catalytic site and prevents interaction with their substrates [10] . Activation of cathepsin proteases is a complex and multistep process that involves the removal of the prodomain region by another protease, or by an autocatalytic mechanism in acidic environments [9, 25] . Cathepsins display optimal activity in acidic environments, with the exception of cathepsin S, which retains most of its activity even at slightly alkaline pH [26] . Nevertheless, despite their natural preference for reducing environments such as the endo-lysosomal vesicles, cathepsins have also been found to act outside the lysosome. In fact, cathepsins were found to participate in ECM remodeling [27] In conclusion, cathepsin activity is highly regulated and it is becoming clear that unbalanced cathepsin activity is a major contributor to vascular injury.
Cysteine cathepsin expression in atherosclerosis
Human tissue analyses show that increased cathepsin expression and activity are implicated in a variety of inflammatory conditions including rheumatoid arthritis, abdominal aortic aneurysms and atherosclerosis [38, 39] In the context of atherosclerosis, lysosomal trafficking mechanisms are considerably important as they go awry during the course of the disease and thus contribute to its pathogenesis. One of the most significant hallmarks in early atheromas is the retention of lipid-laden macrophages in the arterial wall. Normally, intracellular cholesterol levels are kept in very tight balance. This is achieved when cholesterol is recognized by its cell surface receptor, low density lipoprotein receptor (LDLR), and internalized into the lysosomes to liberate free cholesterol [54] . Elevated cholesterol levels are sensed by the endoplasmic reticulum, which immediately turns off the expression of LDLR, driven by the transcription factors sterol regulatory element binding proteins [55, 56] . In atherosclerosis, circulating LDL-cholesterol tends to aggregate in focal regions of the arteries and is prone to chemical modification, especially in the form of oxidation [57, 58] . Modified cholesterol particles are recognized by the innate immune system through a class of pattern recognition receptors such as CD36, scavenger receptor class A and lectin-like oxidized LDL receptor 1. Unlike the LDLR route, cholesterol uptake through this alternative pathway is not subject to negative feedback and thus contributes to cholesterol build-up, especially in macrophages where it triggers the formation of foam cells [59] [60] [61] . Intriguingly, cathepsins were implicated in atherogenic lipoprotein modification in several studies. For example, € O€ orni et al. showed that LDL cleavage by cathepsin F resulted in aggregated and fused lipoprotein particles and this activity was potentiated (up to three-fold) by the presence of proteoglycans [62] . Furthermore, comparative gene expression analysis of human monocytes suggested that cathepsin H is a bona fide lipoprotein modifying enzyme. In vitro analysis further confirmed this hypothesis as incubation of LDL particles with recombinant cathepsin H and cholesterylesterase resulted in foam cell formation and a five-fold increase in macrophage intracellular lipid content [63] . Together these studies provide valuable insight into the contribution of cathepsins to the onset of early atheroma.
Lipoproteins are taken up by LDLR or by alternative routes and delivered to the lysosomes for degradation by acid hydrolyses [64] . Linke et al. [65] emphasized the role of cathepsins in lipoprotein metabolism by showing that cathepsins B, F, K, L and V were able to degrade ApoB-100 under acidic conditions (e.g. pH 5.5).
Since cholesterol is highly reactive substance and mediates numerous biological functions, ingested cholesterol is stored primarily in lipid droplets as cholesterol-ester conjugates [66, 67] . To avoid the cytotoxic effects caused by hypercholesterolemia, macrophages evolved alternative routes to eliminate excess cholesterol, a process known as reverse cholesterol transport (RCT) [68] . RCT involves the hydrolysis of lipid droplets and mobilization of cholesterol to ATP binding cassette members (ABCA1 and ABCG1) that transfer cholesterol to its extracellular acceptors, apolipoprotein Al (Apo-AI) and high density lipoprotein (HDL) [69] (Fig. 2A) . The pivotal role for lysosomal degradation in RCT has been recently addressed by Ouimet et al. who showed that delivery of cholesterol in macrophage foam cells to Apo-AI and HDL is mediated by autophagy. Furthermore, perturbations of this transport mechanism caused by small molecule inhibitors or genetic engineering resulted in decreased cholesterol transport to nascent Apo-AI or HDL [70] .
The significance of cathepsins to cholesterol trafficking and excretion can be inferred from both genetic studies and in vitro models. For example, expression of cathepsins B, F, H and L was lower in monocytes from patients with low HDL levels, a major risk factor for cardiovascular disease, compared with normal agematched subjects [71] . Furthermore, Becker et al. [72] uncovered that cathepsin L is engaged in a protein network that is important for cholesterol homeostasis and is disturbed in lipid-loaded macrophages. While expression studies can only imply a possible relationship between cathepsin function and RCT, studies using cell culture models consolidated this hypothesis. Several independent studies provide compelling evidence that oxidized LDL (oxLDL) particles attenuate cathepsin function, leading to lysosomal cholesterol retention and impaired cholesterol efflux to HDL particles [73] [74] [75] [76] (see Fig. 2B ). In that sense, Oneil and colleagues suggested a direct mechanism using cathepsin B as a model, by which oxidized lipid metabolites attenuate cathepsin activity by forming protein-lipid adducts on reactive cysteine and histidine residues [77, 78] . In addition, cathepsins can hamper cholesterol secretion by digesting nascent HDL particles. For example, cathepsins F and S were shown to cleave prebHDL and thereby impair cholesterol efflux from macrophages [79] . More recently Dinnes et al. elaborated on these observations by showing that cathepsin B, secreted from human monocyte-derived macrophages, impairs cholesterol efflux to HDL by cleaving its core protein, Apo-AI. Mass spectrometry analysis uncovered serine 228 as the cleavage site on Apo-AI and functional studies using truncated protein confirmed its impaired capacity to stimulate RCT [80] (Fig. 2B ).
In conclusion, we provide evidence that cathepsins are important in cholesterol homeostasis and that aberrant cathepsin activity contributes to atheromatous plaque formation through a number of different mechanisms. 
Dysfunctional lysosomes promote vascular inflammation via cathepsins
The inflammatory basis of atherosclerosis is well established [81, 82] . Recent studies linking lysosomal dysfunction to sterile inflammation in hyperlipidemic conditions illuminate the contribution of cathepsins to the progression of atherosclerosis. As macrophages tend to collect cholesterol, their lysosomes become overwhelmed by lipid accumulation and they eventually become dysfunctional [75, 83] . This has shown to be a consequence of CC formation that results from accumulation of oxLDL, consequently triggering an inflammatory response mediated by nucleotide-binding oligomerization domain-like receptor protein (NLRP) inflammasomes and involves cathepsins B and L [84] . Two papers from K. J. Moore's laboratory demonstrated that oxLDL is ingested via CD36 dimers in the Toll-like receptor (TLR) signaling pathway to provide both priming and processing steps required for IL-1b activation in macrophages [85, 86] . In vitro studies demonstrated that macrophages lacking cathepsins B or L secrete less IL-1b in response to CC stimulation, and in vivo these mice displayed decreased neutrophil recruitment in response to CC challenge [84] . Mechanistic studies suggested that CCs disrupted lysosomal membrane integrity and caused the release of lysosomal hydrolases into the cytosol, which provided an alternative pathway for IL-1b processing [84] . In support of this mechanism, macrophages incubated with silica or aluminum mediated lysosomal disruption, suggesting that cathepsin B is released into the cytosol and spearheads IL-1b processing in the absence of caspase-1 [87] (Fig. 2B ). These data, in addition to the recent discovery that cathepsins regulate the transcription and activation of NLRP3 and IL-1b [88] , suggest the mechanisms through which cathepsins promote the inflammatory response under hyperlipidemic conditions.
Cathepsins meet autophagy to manage inflammation and cellular damage
In order to handle the cytotoxic effects of excessive inflammation, cells activate an evolutionarily conserved degradation mechanism known as autophagy [89] . Autophagy is responsible for bulk degradation of damaged proteins and protein aggregates and dysfunctional organelles. Several lines of evidence suggest that dysfunctional autophagy underlies the development of advanced atherosclerotic lesions in part by enhancing cellular inflammation [90] . Cathepsins are highly activated during autophagy, for example the loss of cathepsin L in mouse embryonic fibroblasts impaired lysosomal function and increased cellular oxidative stress [91] . Similar observations were obtained in macrophages when cathepsin S activity was diminished; in this case, dysfunctional autophagy was associated with increased cardiac inflammation [92] . In contrast, reverting lysosomal function through a TFEB knock-in approach in macrophages, effectively improved autophagy and cholesterol clearance and decreased IL-1b secretion [93] . Furthermore, using a recombinant protein therapy approach, Sun et al. [94] were able to enhance lysosomal function, as evident from the levels of mature cathepsins B and L, and reduce vascular inflammation and atherosclerosis burden in mice. Overall, lysosomal cathepsin activity seems to play an important role in the autophagy-lysosomal pathway and is likely to protect against lipotoxicityinduced vascular inflammation.
Cysteine cathepsins in cell death and macrophage clearance
A large necrotic area composed of dead cells and cellular debris is a typical hallmark of advanced atheroma and is the culprit of symptomatic plaques ('unstable plaques'). The development of necrotic regions in atherosclerosis can happen due to primary necrotic cell death or imbalance between apoptosis and clearance of dead cells referred to as 'secondary necrosis' [95] . Necrosis is a special case of cell demise in which intracellular content is released as cells lose their membrane integrity. Atherosclerosis-related bioactive molecules such as monosodium ureate, CCs and ATP are sensed by neighboring cells and elicit an inflammatory immune response driven by pattern recognition receptors and inflammasomes [96] . The involvement of cathepsins in myeloid necrotic cell death has been documented and shown to involve lysosomal membrane permeabilization and cysteine cathepsins B, C and S [97, 98] . Impairment of lysosomal integrity and release of cathepsins to the cytosol is a common feature in atherosclerosis, as described by Duewell et al. [84] , and is likely to contribute to necrotic core formation; however, this mechanism requires further investigation.
Apoptosis is a programmed cell death that enables safe removal of dying cells and prevents the loss of membrane integrity. Apoptotic cells are taken up and digested by the immune system, especially by macrophages in a processed known as efferocytosis [99] . Normally, efferocytosis is efficient and necessary for early stage plaque regression; however, in advanced atheromas this mechanism is overwhelmed by accelerated cell death leading to dysfunctional efferocytosis [100] . The engagement of cathepsins in apoptotic cell death was reported for hyperlipidemia with the presence proinflammatory cytokines [101] [102] [103] [104] . Cathepsin-mediated cell death involves their translocation to the cytosol where they cleave BID and other members of the Bcl-2 family such as Bcl-x and trigger an apoptotic cascade in parallel to or independent of caspase 3 activation [12] . In human atheromas, cathepsins B and L were found in apoptotic phagocytic cells, and in vitro studies further ascertained their redistribution into the cytoplasm and nucleus in the presence of toxic lipid substances [105, 106] . Rapid and efficient efferocytosis is an important mechanism to temper an excessive inflammatory response and prevent atherosclerosis [107, 108] . Exclusion of apoptotic cells by efferocytosis is a multistep process that requires recognition cell signaling cascades and efficient delivery and digestion of cargo by lysosomal proteases. Impaired lysosomal function due to oxidized lipid metabolites has been shown to attenuate apoptotic cell clearance and promote necrotic core formation in LDL À/À mice [109] . Cathepsin L has also been found to be necessary for apoptotic cell clearance in a Caenorhabditis elegans model [110] , in agreement with its importance in lysosomal function [91] . Taken together, these data suggest that cathepsins may play a role in efferocytosis; however, their precise molecular function in the setting of atherosclerosis requires further investigation.
Cysteine proteases in arterial remodeling in atherosclerosis
Cathepsins reshape blood vessels Arterial remodeling is a prominent clinical feature in atherosclerosis. During the early phase of arterial plaque formation, lesions grow away from the lumen and remain clinically undetectable. Later on these fatty streaks enlarge and start to intrude into the lumen and limit blood flow by narrowing the artery, giving rise to clinical symptoms such as ischemia and unstable angina [111] . These physical and structural changes of the blood vessel can happen due to excessive inflammation and proteolysis of the vascular ECM, especially collagen and elastin [112] (Fig. 3) .
Collagen fibers (especially type I and II) have a triple-helical structure and are generally resistant to degradation by cathepsins. An exception is cathepsin K, which is deemed to have physiologically relevant collagenase activity [113] . This unique feature of cathepsin K among other cathepsins is largely attributed to a GAG-cathepsin K complex (especially with chondrotin sulfate 4) and its dimerization with another cathepsin K molecule at the gap regions of packed collagen fibrils [113] [114] [115] . Another distinctive characteristic of cathepsin K is the ability to accommodate proline (Pro) or hydroxyproline (Hyp) at position S2, enabling cleavage of Gly-Pro-X or Gly-X-Hyp, which are common motifs in collagen fibers [17, 112] . This was confirmed by mutation analysis in which replacement of Tyr67 and Leu205 at the S2 position of cathepsin K completely abolished its collagenolytic activity without affecting its gelatinolytic activity [116] .
Elastin is another principal component of the ECM, and is severely damaged during vascular remodeling in atherosclerosis. For example, human atheromas overexpress cathepsins K and S, and protein extracts from these samples enhanced elastin degradation compared with extracts from normal arteries. In addition, stimulation of SMCs with IL-1b or IFN-c stimulated cathepsin S secretion and elastin degradation [41] ; this provides a plausible mechanism for enhanced tissue remodeling in atherosclerosis (Fig. 3) . Moreover, in vitro studies identified human cathepsin V but not cathepsin L as the most potent elastolytic enzyme so far [117] . Mechanistic studies identified the existence of two hydrophobic exosites on cathepsin V that facilitate the binding and recognition of elastin to cathepsin V [118] . Of note, cathepsin V is structurally similar to mouse cathepsin L, which is considered a potent elastase in vivo, and exhibits similar elastolytic activity in vitro to human cathepsin K and S [45, 117] .
A large body of work using genetically engineered mouse models implicated cysteine cathepsins in the genesis of vascular lesions and arterial remodeling [119] inflammatory cell content such as macrophages and T cells [45] . In the case of cathepsin K, animal models yielded confounding results. Animals deficient in cathepsin K on an ApoE À/À background were protected against advanced vascular lesion formation and increased total ECM content [123] . In contrast, adoptive transfer of cathepsin K deficient myeloid cells into LDLR À/À mice resulted in greater plaque macrophage-foam cell content, relatively larger necrotic core, and less elastic lamina fragmentation and plaque collagen content [124] . In support of cathepsin K as a potent ECM proteinase, cathepsin K in humanderived atherosclerotic plaques was found in close proximity to the collagen degradation product CTX-I [125] . Additionally, in vitro studies laid further mechanistic evidence that foam cell-derived cathepsin K can actively degrade collagen type I [125] . These studies demonstrate the need for cell type analysis of cathepsin activity to further clarify the interplay of cysteine cathepsins in the setting of atherosclerosis and suggest a pivotal role for cathepsins in ECM turnover and immune response.
Cathepsins and angiogenesis
Modulating the physical properties of the atherosclerotic plaque, cathepsins have also been shown to be engaged in neovascular formation, a phenomenon that promotes advanced vascular lesions [22, 126] . The new blood vessels provide a channel for infiltrating immune cells, lead to intraplaque hemorrhage and promote plaque destabilization [127] [128] [129] . The involvement of cathepsin S in angiogenesis was previously addressed by Shi et al. using a targeted approach. In their study, they showed that EC from cathepsin S À/À mice failed to generate normal microvessel structures in response to vascular injury [130] . In the context of a cancer microenvironment, cathepsin S-stimulated angiogenesis required the cleavage product of laminin 5 [131] . More recently, cathepsin S has been implicated in a molecular cell signaling cascade in response to ischemia or vascular injury that involved the nuclear receptor peroxisome proliferator activator c and histone deacetylase 6 [132, 133] . Cathepsin L was found to promote vascular angiogenesis after ischemic infliction by promoting endothelial progenitor cell invasion and incorporation into new blood vessels [134] . Finally, cathepsin K was found to stimulate angiogenesis in the context of vascular injury via Toll-like receptor TLR-2/4, and the knockout of cathepsin K reduced neointimal formation, macrophage cell content in focal vascular injury and chemotaxis-stimulating molecules [135] . Another mechanism by which cathepsin K mediated angiogenesis is through processing and activation of the NOTCH 1 pathway [136] . These studies show that promotion of vascular angiogenesis is another aspect of cathepsin involvement in the progression of atherosclerosis.
Harnessing cysteine cathepsins for diagnosis and therapeutics of vascular disorders
Cathepsins as biomarkers for advanced atherosclerotic lesions
In many atherosclerotic patients, vascular lesions are not obstructive and remain silent, displaying no clinical symptoms. Acute coronary syndromes such as myocardial infarction and stroke arise primarily due to vascular thrombosis (Fig. 3) . Plaque rupture is the most frequent cause of arterial thrombosis and is characterized histologically by a thin fibrous cap, high content of inflammatory constituents, a necrotic core and high activity of tissue remodeling proteases. Early detection of these vulnerable plaques remains a great challenge for the prevention of acute coronary events, and therefore much effort has been invested in attempting to identify a molecular signature that discriminates between stable and unstable lesions. Such information would be of considerable importantance for biomarker discovery and would shape novel intervention strategies as we approach the era of precision medicine. Recently, a handful of genes and molecular pathways were reported to discriminate symptomatic and asymptomatic lesions. These included members of the cysteine proteases such as cathepsins B and Z among other tissue remodeling factors such as matrix metalloproteinase [137] . Likewise, we recently reported on altered gene expression pattern and activity of cysteine cathepsins in macrophages from unstable lesions [138] . This molecular information implies that signals emanating from the plaque microenvironment will provide more accurate predictions relating to patient outcome compared with standard assessment techniques [139] . As such, noninvasive molecular imaging is highly appealing for this endeavor. Molecular imaging is a rapidly growing field that is committed to translate novel biomarker discoveries into diagnostic tools. In the case of atherosclerosis, novel methods for detection of protease activity, reflecting an active vascular remodeling process, are continuously emerging.
In general, proteolytic substrates are recognized by the primary amino acid sequence adjacent to the cleavage site within target proteins, and therefore it is possible to target protease activity using molecules based on their recognition sequence [140] . This approach in conjunction with a specific reporter such as a fluorophore or other contrasting agent is widely employed in the field of cardiovascular imaging to capture abnormal protease activity [141, 142] . This is achieved through different classes of affinity-based molecules such as substrate-based probes and activity-based probes (ABPs) (see Refs [143, 144] for comprehensive discussion). Briefly, substrate-based probes are molecules that can change their spectral properties upon enzymatic cleavage (Fig. 4) . For example, ProSense Ò (PerkinElmer, Waltham, MA, USA) is a commercial pan cathepsin substrate-based probe, composed of poly L-lysine embedded in a methoxypolyethylene glycol scaffold [145] . ProSense is self-quenched due to high density of fluorophores and generates a fluorescence signal upon its cleavage, preferably by cathepsins. This polymeric substrate has been widely employed for preclinical cardiovascular imaging [146] [147] [148] [149] . In these studies, fluorescence intensity correlated with vascular inflammation, macrophage content and cathepsin expression. While ProSense, represents an early initiative with substrate-based probes and in some cases displayed slower kinetics compared with modern technologies [150] , the recent advent of lipidated cathepsin substrates looks promising, with improved homing properties over other substrate probes [151] .
In the ABP approach, the molecules are designed to be retained within the enzyme's active site by covalent modification of the protease reactive amino acid side chain; in the case of cysteine protease this is a reactive thiol group. An improved ABP class, quenched ABPs (qABPs) harbor a quenching moiety, which makes them suitable for real-time imaging applications such as in vitro live cell imaging and in vivo imaging [152, 153] . Furthermore, the covalent binding of the enzyme to the small molecule enables downstream analysis, such as by SDS/PAGE. We recently applied this method to human carotid endarterectomy samples to show that cathepsin activity may be used as a surrogate marker to distinguish symptomatic patients [138] . In addition, labeling cathepsin activity with qABP has been successfully implemented in preclinical animal models of atherosclerosis [154] . Using fluorescence molecular tomography we showed that qABPs (GB137) home in on atherosclerotic plaques in mice, and confocal microscopy analysis of tissue sections delineated that the fluorescence signal colocalizes with plaque-associated macrophages [154] .
Reduced light penetrance is one of the major downsides of these fluorescence-based technologies, thus limiting their use to preclinical imaging, invasive clinical procedures and detection of superficial tissue (see [155] for comprehensive discussion). However, the fact that ABPs are retained in tissue expressing high protease activity and can be decorated with tags that enable deeper tissue contrast provides a great advantage over substrate-based probes, and therefore lay the ground for translation of molecular imaging into clinical practice [156] . In that sense, Withana et al. took a major step towards translating molecular imaging into clinical practice by developing a dual-modality ABP for positron emission tomography-computed tomography and optical analysis. That study showed that the novel molecular agent can accurately discriminate between inflamed and normal arteries in vivo, and ex vivo sections from these animals further supported their findings by showing that the fluorescence signal colocalized with activated macrophages [157] . The authors also demonstrated encouraging data using this imaging modality for idiopathic pulmonary fibrosis in human subjects [158] , which further support their utility in the clinical arena.
With the advent of multimodal imaging [159] , such novel contrasting agents can significantly improve the ability to identify rupture-prone atherosclerotic lesions by gathering anatomical and molecular information.
Cathepsin targeted therapy for atherosclerosis
The ability to target potentially dangerous atherosclerotic lesions using ABP or substrates has largely inspired the use of small-molecule inhibitors for preclinical assessment. Two independent studies using cathepsin S inhibitors have successfully attenuated vascular lesion development in ApoE À/À mice. Both studies report on decreased plaques size and macrophage content in mice treated with cathepsin S inhibitor [121, 160] . Figueiredo et al. also provide a compelling mechanism for decreased plaque macrophage content using a cathepsin S inhibitor, through the reduction of chemotactic molecule and growth differentiation factor 15 [160] . A different approach to eliminate inflammatory cells can be achieved through photodynamic therapy (PDT). This uses a photosensitizer agent and a specific wavelength to produce a focal burst of reactive oxygen species and ultimately kill neighboring cells. This approach holds great promise as it increased overall plaque stability and reduced inflammatory cell content in rabbits [161] . On top of its therapeutic benefits, incorporating these photosensitizers into cathepsin-targeted qABP can generate a potent theranostic agent (PS-qABP) that becomes activated on demand. This means that PS-qABP will produce a fluorescence signal/reactive oxygen species when bound to an active protease as shown in cancer mouse models at the site of inflammation [162] . This feature should enable more accurate and effective treatment for potentially deleterious vascular lesions. These benefits prompted the design of a cathepsin B theranostic substrate molecule (L-SR15) using chlorin E6 embedded in polylysine polymer [163] . This study reported encouraging results when PDT light treatment diminished macrophage cell content without having an effect on SMCs and without notable cytotoxic effects in ApoE À/À mice [163] .
One thing to consider with L-SR15 is the requirement for a complicated invasive procedure in order to apply PDT, which highlights the need for an improved design in pursuit of a non-invasive approach. Thus, the high cathepsin expression and activity in atherosclerosis has led to the generation of targeted imaging and therapeutic entities that enable accurate tracking of vulnerable plaques as well as treatment in animal models.
Conclusion and perspectives
Cathepsin activity is versatile and potentially affects almost every critical step in atherogenesis. Over the past decade, a large body of data from humans and rodents emphasizes the role of cathepsins in the etiology of vascular diseases. Early in vitro studies demonstrated that cathepsins are capable of digesting the physical constituents of the vasculature such as collagen and elastin, and therefore much work in vivo has naturally focused on this aspect to investigate their impact on atherosclerosis. Recently, due to a significant increase in risk of stroke, Merck's cathepsin K inhibitor, Odanacatib, was pulled out of clinical trials, despite the promising data with respect to bone mineral density [164] . This dropout emphasizes the importance of cathepsin K's function in the cardiovascular arena. Nevertheless, the increase in stroke using a cathepsin K inhibitor is counterintuitive stressing the lack of comprehensive knowledge on the involvement of cathepsins in cardiovascular pathogenesis. Cathepsins are chiefly lysosomal hydrolases, and beside their significant role in shaping their microenvironment, they participate in several important pathways 'in-house'. One of them is autophagy, which regulates many important features of atherogenesis such as lipid metabolism, inflammation and clearance of damaged cellular components or apoptotic cells. Cathepsins are functionally important to the autophagy-lysosomal pathway, but comprehensive data regarding their specific functions under these conditions are currently lacking.
There is no doubt that future studies will inevitably expand our understanding of the role of cathepsins in atherosclerosis and will potentially help in designing novel therapeutic strategies and avoid cytotoxic effects. An interesting approach to study cathepsin function has recently been introduced by Prudova et al. [165] , who used a sophisticated mass spectrometry approach to explore the contribution of cathepsins in the context of pancreatic cancer. We strongly believe that such methodologies are valuable and are likely to expand our future understanding of the physiological roles of cathepsins in atherosclerosis. From a translational perspective, cathepsin activity provides a promising target for future theranostic agents in attempts to identify rupture-prone plaques. 
